Today's Healthcare Pulse
Allogene Therapeutics CEO David Chang to step down
Allogene Therapeutics announced that chief executive David Chang will leave his role. The news was reported by STAT+ and echoed in a follow‑up piece covering broader pharma updates.
Also developing:
By the numbers: Boston Scientific invests $1.5B for 34% stake in MiRus
Evercore Maintains Positive Stance on MeiraGTx Holdings Plc (MGTX) Amid Sector Revisions
Evercore ISI analyst Gavin Clark‑Gartner lowered his price target for MeiraGTx Holdings (MGTX) from $20 to $18 while maintaining an Outperform rating, part of a sector‑wide revision of small‑ and mid‑cap biotech firms. The adjustment follows the FDA’s recent Breakthrough Therapy Designation for MGTX’s AAV2‑hAQP1 gene therapy targeting radiation‑induced xerostomia, and ongoing Phase 2 work aimed at a future biologics license application. Evercore highlighted that biotech stock performance will increasingly hinge on full‑year 2026 milestones, suggesting longer‑term catalysts remain central to valuation. The firm also contrasted MGTX’s upside with perceived higher returns in AI equities.
Morgan Stanley Updates Bicycle Therapeutics Plc (BCYC) Outlook Amid Pipeline Refocus
Morgan Stanley lowered its price target for Bicycle Therapeutics plc (BCYC) to $12 from $13, while maintaining an Equal Weight rating, reflecting a revised valuation after the company refocused its pipeline on BT5528 and next‑generation Bicycle conjugate programs. The shift...
Jefferies Sees Reduced Upside for Arbutus Biopharma Corporation (ABUS) on Higher Appeal Probability
Jefferies lowered its price target for Arbutus Biopharma (ABUS) from $7.00 to $5.50 while keeping a Buy rating, citing a higher probability that Moderna will win its appeal in a patent dispute. The appeal outcome affects a potential $1.3 billion contingent...
Mizuho Sees Strong Risk-Reward in Corbus Pharmaceuticals Holdings, Inc. (CRBP) Near Cash Value
Mizuho Securities raised its price target on Corbus Pharmaceuticals (CRBP) to $40, maintaining an Outperform rating after the company’s fourth‑quarter results. The firm highlighted that CRBP is trading near its cash balance, which it says caps downside risk. Mizuho expects...
Northland Highlights ARS Pharmaceuticals, Inc. (SPRY) Needle-Free Therapy as Major Innovation Driver
Northland Research initiated coverage of ARS Pharmaceuticals (NASDAQ:SPRY) with an Outperform rating and a $25 price target, spotlighting its needle‑free epinephrine spray, Neffy, as a growth catalyst. The U.S. FDA recently revised Neffy’s labeling, removing the previous age restriction and...
Jefferies Sees Reduced Visibility for Replimune Group, Inc. (REPL) Following FDA Decision
Jefferies downgraded Replimune Group (NASDAQ:REPL) from Buy to Hold and slashed its price target to $2 after the FDA issued a complete response letter on the RP1 oncolytic therapy. The FDA’s feedback diverged from earlier Type A meeting guidance, raising...
Evercore Adjusts Fortrea Holdings Inc. (FTRE) Valuation Following Updated Near-Term Assumptions
Evercore ISI trimmed Fortrea Holdings (FTRE) price target to $14 from $25 while keeping an Outperform rating, citing revised near‑term assumptions in its Q1 healthcare technology update. The change coincides with FTRE’s launch of Fortrea Intelligent Technology (FIT), an AI‑enabled...
India Discharges Knee Replacements in Days, Not Months
WHY YOU SEE MANY FOREIGNERS IN INDIAN HOSPITALS 🥼🩺 Knee replacement surgery waiting times 🇵🇱 Poland – 253 days 🇦🇺 Australia – 209 days 🇪🇸 Spain – 147 days 🇨🇦 Canada – 122 days 🇬🇧 UK – 98 days 🇮🇳 India...
How Technology Is Helping Healthcare Teams Spend Less Time on Non-Clinical Tasks
Healthcare providers are increasingly turning to technology to offload non‑clinical tasks that drain clinician time. Remote billing specialists, AI‑driven scribing, automated scheduling and website chatbots are among the tools gaining traction. These solutions promise to reduce documentation errors, cut call...
STAT+: FDA Eyes Expanding Testosterone Therapy for Libido
The FDA is reviewing data that could broaden testosterone‑replacement therapy to include low libido as an approved indication, a move that would extend the drug’s market beyond hypogonadism. If cleared, the label change could add roughly $1.5 billion in annual U.S....
Lilly’s Foundayo Reaches 1,390 Patients in First Week, Trailing Novo’s Oral Wegovy Launch
Eli Lilly’s newly approved oral obesity drug Foundayo recorded 1,390 prescriptions in its first two days, a modest start compared with Novo Nordisk’s oral Wegovy, which logged over 3,000 patients in its inaugural week. RBC Capital Markets noted the timing difference—Foundayo launched...
MD Pharmaceutical Supply, LLC - 637815 - 04/13/2026
The FDA has finished reviewing MD Pharmaceutical Supply’s corrective actions taken after a warning letter issued in November 2022. The agency concluded that the company appears to have addressed the cited deviations, but it emphasized that future inspections will assess...
Biovac Gets $108M Backing for Vaccine Factory in South Africa
Biovac announced that its new vaccine manufacturing complex in Cape Town has secured $108 million in financing from the European Investment Bank, the European Commission, and the International Finance Corporation. The plant is designed to produce up to 400 million doses per...
Goldman Sachs, General Atlantic, Aquitaine Back Autism Care; Supply-and-Demand Gap Drives Scaling Opportunities in Mental Health Assets
Goldman Sachs Alternatives, General Atlantic and Aquitaine are backing a growing autism‑care platform, citing a stark supply‑and‑demand mismatch in mental‑health services. Their investments follow MKH Capital Partner’s recent acquisition of a network of mental‑health and substance‑use treatment centers, highlighting a...
![[Perspectives] Refiloe Masekela: Building Access to Care for Childhood Lung Disease](https://hixhlmpcokxhartfkpyi.supabase.co/storage/v1/object/public/images/thumbnails/4d80850fccb4290715011ebe5c9ab6b6.webp)
[Perspectives] Refiloe Masekela: Building Access to Care for Childhood Lung Disease
Refiloe Masekela, a paediatric pulmonologist and dean at the University of KwaZulu‑Natal, reflects on South Africa’s early‑2000s HIV crisis that left many children dying from respiratory complications before antiretroviral therapy became widely available. She now spearheads initiatives to broaden access...
GLP-1 ‘Halo Effect’: Users Positively Impact Household Eating Habits
Acosta Group’s report finds that GLP‑1 weight‑loss drugs are sparking a “halo effect” that extends beyond users to other household members. Users, especially Gen Z and Millennials, report emotional boosts that translate into higher spending on fresh produce, yogurt, and protein‑rich...
New Study Shows Proven Strategies to Reignite Meaning for Burned‑Out Physicians
A new GlobalRPH research paper outlines evidence‑based interventions that restore meaning and motivation for burned‑out healthcare workers. The study cites that over half of U.S. physicians experience burnout, costing the system more than $4.6 billion annually, and proposes organizational changes that...
Idaho Falls Educator Wendy Welch Nominated for 2026 National Home Visitor of the Year
Wendy Welch, a parent educator with Eastern Idaho Public Health, has been nominated for the 2026 National Home Visitor of the Year. Her bilingual outreach to Spanish‑speaking families and support for incarcerated parents earned her a spot among 179 nominees,...
Physiotherapist Urges Back‑Prep Routine for Runners Returning After Break
Physiotherapist Belén García of Rekovery Clinic advises runners who have been sedentary to follow a back‑preparation routine before hitting the pavement, warning that the impact of running can overload the lumbar spine. She notes that while knee injuries are common,...
Revolution Medicines' Buyout Price Soars After Pancreatic Cancer Win
Revolution Medicines announced positive Phase 3 data for its pancreatic cancer candidate, showing a statistically significant survival benefit. The breakthrough lifted the company’s market value from roughly $30 billion to an estimated $45 billion, reigniting speculation of a mega‑buyout. Investors rushed in, sending...
FDA's Proposed Peptide Rule Change Boosts Hims & Hers, Sends Mixed Signals Across Pharma
The U.S. Food and Drug Administration announced a review to lift 12 peptides from Category 2 restrictions, prompting a 9% jump in Hims & Hers stock and sparking broader industry debate over compounded peptide therapies.
CMS-0062: An Intra-Agency Cold War Goes Hot
CMS issued two conflicting rules within three weeks, each designating a different HIPAA standard for attaching clinical documentation to payer‑provider transactions. On March 20, 2026, CMS‑0053 finalized X12N 275 as the standard for claim attachments, a long‑awaited adoption. Ten days later, CMS‑0062...
MeitY Selects 10 AI Startups, Including Health‑tech Firms, for Second IndiaAI Cohort
India’s Ministry of Electronics and Information Technology (MeitY) announced the selection of ten artificial‑intelligence startups – two of them health‑tech focused – for the second cohort of the IndiaAI Global Acceleration Programme. The cohort will undergo a three‑week online prep...
STAT+: Pharmalittle: We’re Reading About Lilly Weight Loss Pill Trial Results, Slashed U.K. Clinical Trial Times, and More
Researchers led by Richard DiMarchi and Matthias Tschöp reported a novel GIP‑glucagon dual agonist that may achieve weight loss comparable to GLP‑1 drugs without the typical nausea and vomiting. In parallel, Eli Lilly announced that its new obesity pill Foundayo lowered...
RFK Jr. Grilled by House Democrats over Vaccine Stance as Measles Cases Surge
Health and Human Services Secretary Robert F. Kennedy Jr. faced a hostile hearing before the House Ways & Means Committee, where Democrats pressed him on his anti‑vaccine record and a jump to 1,714 measles cases this year. The hearing also highlighted a $415 million...
Abbott Beats Q1 Sales, Raises FY26 Outlook After Exact Sciences Deal
Abbott Laboratories reported first‑quarter 2026 revenue of $11.16 billion and adjusted earnings per share of $1.15, a 6% year‑over‑year rise. The company updated full‑year guidance to 6.5%‑7.5% comparable sales growth and $5.38‑$5.58 adjusted EPS, reflecting the $3 billion sales contribution and $0.20...
Juvisé Pharmaceuticals Names Renaud Sermondade CEO, Frédéric Mascha Executive Chairman
Juvisé Pharmaceuticals announced that founder Frédéric Mascha will step down as chief executive and assume the role of Executive Chairman and President of the Supervisory Board, while Renaud Sermondade will take over as CEO on July 1, 2026. The move follows a board...
MD Pharmaceutical Supply, LLC - 637815 - 11/22/2022
The FDA issued a warning letter to MD Pharmaceutical Supply, LLC after an April‑May 2022 inspection uncovered multiple CGMP violations at its Hanover, PA drug repackaging facility. The agency cited failures to investigate returned API complaints, inadequate temperature and humidity...
Future-Ready Pharma Summit
The Future‑Ready Pharma Summit gathered analytical scientists, lab managers and decision‑makers to showcase how automation, AI and digital services are reshaping small‑molecule pharmaceutical chromatography. Sessions covered AI‑driven LC method optimization, collaborative dissolution workflows, and sustainability‑focused regulatory guidance such as USP...
Hospices’ Top Questions About AI
Hospice providers are rapidly adopting AI to streamline operations and support clinical decisions, with 36% naming predictive analytics as their top technology investment for 2026. The rollout spans functions from scheduling and documentation to medication management and family communication. However,...
Speaking with One Voice to Advance Health in America
The American Hospital Association will host its 2026 Annual Membership Meeting in Washington, D.C., drawing more than 1,000 health‑care leaders. Attendees will hear policymakers, discuss the looming midterm elections, and coordinate a unified advocacy push on three priority issues: access...
Taiwanese Universities Unveil Green Nanorod Sensor Platform with 0.21 µM Detection Limit
Researchers from National Central University and National Taipei University of Technology have built a green nanorod‑based electrochemical sensor that detects adrenaline at a limit of 0.21 µM. The platform uses coffee‑acid reduction to embed rhenium nanoparticles in hollow ZnMn₂O₄ microspheres, offering...
Racist Claim Blames Parenting, Ignores Black Mental Health Disparities
Why do I say this statement is not only wrong, but racist? 1. It implies Black children's mental health problems are all due to parenting, & that the only answer is to adopt them out. 2. It ignores actual disparities in care,...
Therapy for Brain Injuries in Infants Bags Funding: Is the First HIE Drug on the Way?
ReAlta Life Sciences raised $40 million to finish its phase 2 STAR trial of pegtarazimod, a first‑in‑class drug that blocks both complement C1 and neutrophil pathways to treat hypoxic‑ischemic encephalopathy (HIE) in newborns. HIE affects about 8,000 U.S. infants annually, causing 15‑20%...
Alamar Biosciences Upsizes IPO, Raises $191.3 M to Accelerate Cell‑Based Drug Discovery
Alamar Biosciences priced an upsized initial public offering of 11.25 million shares at $17 each, generating $191.3 million in gross proceeds. The capital will fund the expansion of its cell‑based drug discovery platform, positioning the company for broader partnerships and a Nasdaq...
AssureCare CEO on the AI-Powered Platform Unifying Patient Engagement Across Healthcare
AssureCare has launched Aktivate, an AI‑powered patient engagement platform that unifies data, communication channels, and decision‑making across providers, payors, pharmacies, and care teams. The platform orchestrates outreach, using real‑time insights to deliver the right message at the right time and...
Article Intro - White Paper on Surgical Robot Certification
TÜV SÜD has released a detailed white paper on global market entry for surgical robotics, highlighting how the EU Medical Device Regulation now governs these systems and how the forthcoming AI Act will add another compliance layer. The paper outlines...
Not Every Medical Mistake Makes Headlines — But They Happen Every Day
A recent Florida case in which a surgeon removed the wrong organ highlights the stark reality that medical errors are far more common than headlines suggest. Studies from Johns Hopkins and the CDC estimate that preventable harm affects up to...
Medicare Can Save $4 Billion On Four Cancer Drugs – Can You Guess Which Ones?
The Inflation Reduction Act authorizes Medicare to negotiate drug prices, starting with ten high‑spending products and expanding each year. By targeting four oncology drugs—Pomalyst, Ibrance, Xtandi and Imbruvica—Medicare could save over $4 billion, with Imbruvica alone offering more than $1 billion in...
Stakeholders Urge Labor Department to Finalize PBM Transparency Rule
Employers, lawmakers and patient groups urged the Labor Department to finalize a rule that forces pharmacy benefit managers (PBMs) to disclose detailed compensation data, including rebates and spread‑pricing. The DOL’s proposal, released in January, would require PBMs to share dollar‑level...
Obesity, GLP-1s, and Metabolic Care
In an interview, hVIVO’s Chief Medical Officer Professor Thomas Forst explains how GLP‑1 receptor agonists have reshaped obesity treatment by targeting metabolic dysfunction rather than just weight loss. He highlights that these drugs reduce cardiovascular events, improve renal outcomes and...
Essential AI Visual Guide for Modern Physicians
A visual guide to machine and deep learning subtypes that is from our npj Digital Medicine paper: A short guide for medical professionals in the era of artificial intelligence. In that, we aimed to create a short, visual and digestible repository...
EQT Revives Sale of Contact Lens Maker Ginko at $1bn-Plus Valuation
Swedish private‑equity firm EQT has re‑opened the sale process for Ginko, a leading European contact‑lens manufacturer, seeking a valuation north of $1 billion. The move follows a brief pause earlier this year as EQT reassessed market conditions. Ginko reported a 15%...
Metformin Misses Target in Type 1 Diabetes Trial
As a medical school professor, I love when medicine humbles us. Metformin has been around for a century. We thought we understood it. We were wrong. A new clinical trial gave metformin to people with type 1 diabetes -- not type 2....
This Everyday Blood Sugar Pattern Is Linked To 69% Higher Alzheimer's Risk
A genetic analysis of more than 350,000 UK Biobank participants found that individuals genetically predisposed to higher blood‑sugar levels two hours after eating face a 69% greater risk of developing Alzheimer’s disease. The same study showed no significant association between...
RFK Jr. Defends Makary, Claims Pharma ‘Owns’ Congress and Media
Health Secretary Robert F. Kennedy Jr. defended FDA Commissioner Marty Makary during a Ways and Means Committee hearing, praising the agency’s recent drug‑approval record and rejecting criticism from the pharmaceutical industry. He highlighted the FDA’s decision to reject Replimune’s oncolytic...
NIH Researchers Discover Pain-Relieving Drug with Minimal Addictive Properties
NIH scientists have identified a novel nitazene‑derived opioid, DFNZ, that delivers potent, two‑hour pain relief in rats without causing respiratory depression, tolerance or significant withdrawal. The compound briefly enters the brain yet sustains analgesia, and unlike traditional opioids it fails...
After 25 Years Of Consumer-Directed Healthcare, What’s Missing?
After two decades of consumer‑directed health policies, the market still lacks the tools needed for patients to act as shoppers. While price‑transparency rules and AI‑driven APIs exist, most care decisions remain embedded in provider referrals and opaque benefit designs, limiting...
LEO Pharma’s Enstilar Receives the NMPA Approval for Plaque Psoriasis
LEO Pharma’s topical aerosol foam Enstilar, combining calcipotriene and betamethasone dipropionate, received approval from China’s National Medical Products Administration for adult plaque psoriasis. The approval follows a Phase III trial of 604 Chinese patients that demonstrated superior efficacy and safety versus...
Join Dr. Robert Califf on Future of Drug Regulation
We are so excited to host Dr. Robert Califf on April 20th, 2026, at 3pm EST. From leading the U.S. Food and Drug Administration to shaping the future of clinical research and drug regulation, Dr. Califf has been at the center...